Edgewise Therapeutics faces challenges with DMD/BMD programs, upcoming trial data concerns, and competitive risks.

In a recent move that has caught the attention of investors, R. Michael Carruthers, the Chief Financial Officer of Edgewise ...

Get the latest news and real-time alerts from Edgewise Therapeutics, Inc. (EWTX) stock at Seeking Alpha. Skip to content Home page Seeking Alpha - Power to Investors ...

ZUG, Switzerland and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Another element that sets digital therapeutics apart was outlined by Ben Lewis, CEO of Limbix, a developer of prescription digital therapeutics, who told pharmaphorum that the company has a ...

DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV ...

Click Therapeutics' digital therapeutic (DTx) CT-132 has been approved by the FDA, becoming the first treatment of its type in the US for preventing attacks in people with episodic migraine.

Consequently, RNAi therapeutics as a drug class have the potential to exert a transformational effect on modern medicine. In RNAi, the target mRNA is enzymatically cleaved, leading to decreased ...